A reassuring set of interims with encouraging signs the refined strategy under EKF’s new CEO is having a positive impact. Strong performances from key focus areas such as Point-of-Care Haematology and high margin -HB sales in Life Sciences are coupled with encouraging lead indicators over pipeline opportunities. Margins continue to improve and cash generation remains strong. We make no changes to our forecasts and remain attracted to the value on offer and strong and growing cash position. We reiterate our BUY recommendation of 37p TP.
